Core Viewpoint - Multiple companies, including Tencent Holdings and China Hongqiao, conducted share buybacks on August 20, 2025, with Tencent leading in both volume and monetary value [1]. Group 1: Buyback Details - Tencent Holdings (00700) repurchased 934,000 shares for a total of 551 million [2]. - China Hongqiao (01378) repurchased 3,318,000 shares for a total of 784.03 million [2]. - Other notable buybacks include: - Techtronic Industries (00669): 250,000 shares for 25.19 million [2]. - Hang Seng Bank (00011): 200,000 shares for 22.37 million [2]. - Guochuang Tongqiao-B (02190): 100,000 shares for 2.32 million [2]. Group 2: Year-to-Date Buyback Performance - Year-to-date buyback totals for selected companies include: - Tencent Holdings: 40,267,000 shares, representing 0.438% of total shares [2]. - China Hongqiao: 52,641,500 shares, representing 0.560% of total shares [2]. - Techtronic Industries: 750,000 shares, representing 0.041% of total shares [2]. - Other companies with significant year-to-date buybacks include: - Maple Leaf Education (01317): 4,903,200 shares, representing 1.650% of total shares [2]. - Yanzheng Technology (02488): 2,190,500 shares, representing 1.356% of total shares [2].

Group 1 - The company, Guichuang Tongqiao, repurchased 100,000 shares at an average price of HKD 23.20, totaling approximately HKD 2.32 million, with a cumulative repurchase of 4.0145 million shares this year, representing 1.26% of the total share capital [1] - As of the market close on the same day, Guichuang Tongqiao's stock price decreased by 1.18%, closing at HKD 23.38 per share [1] - Stock repurchase is typically a strategy employed by management when they believe the company's stock is undervalued, indicating confidence in future development despite market perceptions [1] Group 2 - Guichuang Tongqiao is an innovative medical device company listed on the Hong Kong Stock Exchange, focusing on the research, production, and sales of neuro and peripheral vascular interventional medical devices [2] - The company invests significantly in technology research and development, holding a series of proprietary technologies, and its product range includes various interventional medical devices such as stents [2] - With the growing demand for interventional treatments in the medical industry, Guichuang Tongqiao faces opportunities for development while also needing to address market competition and technological advancements [2]

智通财经APP讯，归创通桥(02190)公布，2025年8月20日耗资约232.03万港元回购10万股股份。 ...

Group 1 - The company, Guichuang Tongqiao (02190.HK), announced a share buyback on August 20, 2023, spending HKD 2.32 million to repurchase 100,000 shares [1]

Group 1 - The company, Guichuang Tongqiao (02190), announced a share buyback plan to repurchase 100,000 shares at a cost of approximately HKD 2.3203 million on August 20, 2025 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 歸創通橋醫療科技股份有限公司 呈交日期： 2025年8月20日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02190 | 說明 | H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | ...

Core Viewpoint - Guichuang Tongqiao reported strong financial performance for the first half of 2025, with significant growth in both revenue and net profit, driven by the expansion of its neurovascular and peripheral vascular intervention businesses [1][2]. Financial Performance - The company achieved operating revenue of 482 million yuan, a year-on-year increase of 31.7% [1]. - Net profit reached 121 million yuan, reflecting a year-on-year growth of 76.0% [1]. - The neurovascular intervention business generated approximately 304 million yuan in revenue, up 25.0% year-on-year, while the peripheral vascular intervention business saw revenue of about 176 million yuan, a 46.2% increase [1]. Operational Efficiency - The company improved operational efficiency, with research and development, sales, and management expense ratios decreasing by 7 percentage points compared to the same period last year [1]. - The company has established a wide distribution network covering over 3,000 hospitals [2]. International Business Growth - Guichuang Tongqiao's overseas business showed rapid growth, achieving operating revenue of 15.72 million yuan [1]. - The company has 22 products commercialized in 27 countries and regions, with over 31 products in the registration process across 23 countries [1]. - The overseas revenue proportion is steadily increasing, becoming a new growth driver for the company [1]. Product Development and Innovation - The company has a product pipeline of 73 items, with 50 approved by the National Medical Products Administration (NMPA) [2]. - New products launched this year include the ZYLOX Eagle thrombectomy system and the Tongqiao Shunfeng balloon hemostatic device, enhancing the product matrix [2]. - The company focuses on differentiated innovation to meet unmet clinical needs, aiming to provide comprehensive solutions for patients [2][3]. Future Outlook - Guichuang Tongqiao aims to expand market share through procurement and enhance international business layout to improve global market coverage [3]. - The company is committed to developing differentiated innovative products with real clinical value to ensure long-term stable growth [3].

Core Insights - The company achieved a revenue of RMB 482 million in the first half of 2025, representing a year-on-year growth of 31.7%, primarily driven by sales growth in the neurovascular and peripheral vascular intervention device segments [1] - Net profit increased by 76% to RMB 121.2 million, while adjusted net profit grew by 68.1% to RMB 131.4 million [1] - Research and development expenses rose by 19.7% to RMB 121.6 million, aimed at new product launches and innovation in the product pipeline [1] Revenue and Profitability - International business revenue saw a significant increase of 36.9%, with products now covering seven of the top ten global markets [1] - The company has established strategic partnerships with over 60 local partners, expanding its channel coverage to 52 countries and regions worldwide [1] Market Presence and Strategy - The company is actively conducting post-market clinical follow-up trials for CE-marked products in Europe to enhance quality recognition and brand awareness [1] - Support has been garnered from well-known hospital groups such as Asklepios and SANA, indicating strong market positioning and credibility [1]

Major Events - CSPC Pharmaceutical Group (01093) received clinical trial approval for Dupilumab injection in China [1] - Rongchang Biopharmaceutical (09995) was granted breakthrough therapy designation for RC148 for non-small cell lung cancer by the National Medical Products Administration [1] - China Biologic Products (01177) included LM-302 "CLDN18.2 ADC" in the breakthrough therapy program [1] - Sunshine Oilsands (02012) plans to acquire 51% stake in Noble Technology Limited for HKD 50.91945 million [1] - Galenica Pharmaceutical-B (01672) plans to issue shares at a discount of approximately 9.9%, raising HKD 468 million [1] Financial Performance - Xiaomi Group-W (01810) reported record high revenue and profit for Q2, with attributable profit of HKD 11.904 billion, up 133.51% year-on-year [1] - Pop Mart (09992) announced a mid-term profit of HKD 4.574 billion, a year-on-year increase of 396.5% [1] - Fuyao Glass (03606) reported a half-year net profit of approximately HKD 4.805 billion, up 37.33% year-on-year [1] - China Resources Beer (00291) announced a mid-term profit of HKD 5.789 billion, an increase of 23.04% year-on-year [1] - Kunlun Energy (00135) reported a mid-term profit of HKD 3.161 billion, down 4.36% year-on-year, with a dividend of HKD 0.166 per share [1] - WuXi Biologics (02269) reported a mid-term profit of approximately HKD 2.339 billion, up 56% year-on-year [1] - Sunny Optical Technology (02382) announced a mid-term profit of HKD 1.646 billion, an increase of 52.56% year-on-year [1] - Yixin Group (02858) reported an adjusted net profit of HKD 648 million, up 28% year-on-year [1] - Kangchen Pharmaceutical (01681) reported a mid-term profit of HKD 498 million, up 24.6% year-on-year, maintaining market leadership with its flagship product [1] - Ping An Good Doctor (01833) reported a mid-term profit of HKD 134 million, a year-on-year increase of 136.84% [1] - China Communication Services (02342) reported a mid-term profit of HKD 61.781 million, returning to profitability [1] - XPeng Motors-W (09868) achieved record levels in core business and financial metrics for Q2, with a net loss of HKD 480 million, narrowing by 62.8% year-on-year [1] - Guochuang Tongqiao (02190) reported a mid-term profit of HKD 121 million, up 76% year-on-year [1] - Yanda Pharmaceutical (00512) reported record revenue of HKD 6.107 billion [1] - Jinli Permanent Magnet (06680) reported a mid-term profit of approximately HKD 305 million, up 154.81% year-on-year [1] - Zhaogang Group-W (06676) issued a profit warning, expecting a mid-term profit of approximately HKD 140 million to HKD 180 million, returning to profitability [1] - Longyuan Power (00916) reported a mid-term profit of HKD 3.519 billion, down 14.4% year-on-year [1] - Yancoal Australia (03668) reported a mid-term profit of AUD 16.3 million, down 61.19% year-on-year [1] - SF Holding (06936) reported total revenue of HKD 24.847 billion for July in logistics, supply chain, and international business, up 9.95% year-on-year [1] - Chow Sang Sang (00116) expects a mid-term profit from continuing operations of approximately HKD 900 million to HKD 920 million [1]

Core Viewpoint - Guichuang Tongqiao Medical Technology Co., Ltd. reported strong financial performance for the first half of 2025, with significant growth in both revenue and net profit [1] Financial Performance - The company achieved a revenue of 482 million yuan, representing a year-on-year increase of 31.7% [1] - Net profit exceeded 121 million yuan, showing a year-on-year growth of 76% [1] Business Segments - The neurovascular intervention segment generated approximately 304 million yuan in revenue, reflecting a year-on-year growth of 25% [1] - The peripheral vascular intervention segment reported revenue of about 176 million yuan, with a year-on-year increase of 46.2% [1] International Operations - Overseas business generated revenue of 15.72 million yuan, with 22 products commercialized in 27 countries and regions [1] - The company is advancing the registration of over 31 products in 23 countries and regions, with global coverage in 52 countries and regions [1] - Collaborations have been established with more than 60 local partners [1]